



## Patents

*U.S. patents issued or exclusively licensed to Osiris Therapeutics, Inc.*

1	Method for Implantation and Differentiation of MSCs <i>Issued March 30, 1993</i>	US 5,197,985 <a href="#">Full patent text</a>
2	Method for Treating Connective Tissue Disorders <i>Issued July 13, 1993</i>	US 5,226,914 <a href="#">Full patent text</a>
3	Human Mesenchymal Stem Cells <i>Issued January 23, 1996</i>	US 5,486,359 <a href="#">Full patent text</a>
4	Transduced Mesenchymal Stem Cells <i>Issued January 7, 1997</i>	US 5,591,625 <a href="#">Full patent text</a>
5	Monoclonal Antibodies for Human Osteogenic Cell Surface Antigens <i>Issued July 1, 1997</i>	US 5,643,736 <a href="#">Full patent text</a>
6	Enhancing Marrow Engraftment using MSCs <i>Issued March 31, 1998</i>	US 5,733,542 <a href="#">Full patent text</a>
7	Lineage-Directed Induction of hMSC Differentiation <i>Issued April 7, 1998</i>	US 5,736,396 <a href="#">Full patent text</a>
8	Connective Tissue Regeneration Using hMSC Preparations <i>Issued September 22, 1998</i>	US 5,811,094 <a href="#">Full patent text</a>
9	Adipogenic Differentiation of Human MSCs <i>Issued October 27, 1998</i>	US 5,827,740 <a href="#">Full patent text</a>
10	Monoclonal Antibodies for Human MSCs <i>Issued November 17, 1998</i>	US 5,837,539 <a href="#">Full patent text</a>
11	Biomatrix for Soft Tissue Regeneration <i>Issued January 5, 1999</i>	US 5,855,619 <a href="#">Full patent text</a>
12	Chemically Defined Medium for hMSCs <i>Issued June 1, 1999</i>	US 5,908,782 <a href="#">Full patent text</a>
13	In Vitro Chondrogenic Induction of hMSCs <i>Issued June 1, 1999</i>	US 5,908,784 <a href="#">Full patent text</a>
14	Lineage-Directed Induction of hMSC Differentiation <i>Issued August 24, 1999</i>	US 5,942,225 <a href="#">Full patent text</a>
15	Isolating MSCs Associated with Megakaryocytes <i>Issued October 12, 1999</i>	US 5,965,436 <a href="#">Full patent text</a>
16	Enhancing Hematopoietic Progenitor Engraftment Using MSCs <i>Issued January 4, 2000</i>	US 6,010,696 <a href="#">Full patent text</a>
17	Ligands that Modulate MSC Differentiation	US 6,022,540

	<i>Issued February 8, 2000</i>	<a href="#">Full patent text</a>
18	In vitro Maintenance of Hematopoietic Stem Cells <i>Issued February 29, 2000</i>	US 6,030,836 <a href="#">Full patent text</a>
19	Monoclonal Antibodies for Human MSCs <i>Issued July 11, 2000</i>	US 6,087,113 <a href="#">Full patent text</a>
20	Antigen Presenting Cells of the Adipocyte Lineage <i>Issued November 21, 2000</i>	US 6,149,906 <a href="#">Full patent text</a>
21	Biomatrix for Soft Tissue Regeneration Using MSCs <i>Issued January 16, 2001</i>	US 6,174,333 <a href="#">Full patent text</a>
22	Production of Megakaryocytes by the Use of Human Mesenchymal Stem Cells <i>Issued May 1, 2001</i>	US 6,225,119 <a href="#">Full patent text</a>
23	Inhibition of Osteoclastogenesis <i>Issued May 29, 2001</i>	US 6,239,157 <a href="#">Full patent text</a>
24	Regulation of Hematopoietic Stem Cell Differentiation by the Use of Human Mesenchymal Stem Cells <i>Issued July 3, 2001</i>	US 6,255,112 <a href="#">Full patent text</a>
25	Human Mesenchymal Stem Cells from Peripheral Blood <i>Issued July 17, 2001</i>	US 6,261,549 <a href="#">Full patent text</a>
26	A Method of Preparing Suppressor T Cells with Allogeneic MSCs <i>Issued August 28, 2001</i>	US 6,281,012 <a href="#">Full patent text</a>
27	Adipogenic Differentiation of hMSCs <i>Issued November 27, 2001</i>	US 6,322,784 <a href="#">Full patent text</a>
28	MSCs for the Prevention and Treatment of Immune Responses in Transplantation <i>Issued December 11, 2001</i>	US 6,328,960 <a href="#">Full patent text</a>
29	Human Slit Polypeptide and Polynucleotide Encoding Same <i>Issued January 29, 2002</i>	US 6,342,370 <a href="#">Full patent text</a>
30	Uses for Non-autologous Mesenchymal Stem Cells <i>Issued March 12, 2002</i>	US 6,355,239 <a href="#">Full patent text</a>
31	Polynucleotides Encoding Human HOX C10 <i>Issued March 19, 2002</i>	US 6,358,702 <a href="#">Full patent text</a>
32	Mesenchymal Stem Cells for Prevention and Treatment of Immune Responses in Transplantation <i>Issued April 9, 2002</i>	US 6,368,636 <a href="#">Full patent text</a>
33	Ligands That Modulate Differentiation of MSCs <i>Issued April 30, 2002</i>	US 6,379,953 <a href="#">Full patent text</a>
34	Cardiac Muscle Regeneration Using Mesenchymal Stem Cells <i>Issued May 14, 2002</i>	US 6,387,369 <a href="#">Full patent text</a>
35	Human Mesenchymal Stem Cells <i>Issued May 14, 2002</i>	US 6,387,367 <a href="#">Full patent text</a>
36	Biological Material for the Repair of Connective Tissue Defects Comprising Mesenchymal Stem Cells and Hyaluronic Acid Derivative <i>Issued November 19, 2002</i>	US 6,482,231 <a href="#">Full patent text</a>
37	Multilayer Skin or Dermal Equivalent Having a Layer Containing Mesenchymal Stem Cells	US 6,497,875 <a href="#">Full patent text</a>

*Issued December 24, 2002*

38

Multilayer Skin or Dermal Regeneration and Augmentation of Bone  
Using Mesenchymal Stem Cells  
*Issued April 1, 2003*

US 6,541,024

[Full patent text](#)

Osiris Therapeutics, Inc. :: 2001 Aliceanna Street :: Baltimore, MD 21231 :: 410.522.5005 :: Fax 4

©Copyright Osiris Therapeutics, Inc., 2003